GLSIライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers...

Stats
本日の出来高	27 889.00
平均出来高	52 203.00
時価総額	168.96M
EPS	$0 ( 2024-03-29 )
次の収益日	( $-0.200 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-19.01
ATR14	$0.170 (1.31%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Patel Snehal	Buy	3 000	Common Stock
2024-03-22	Patel Snehal	Buy	2 500	Common Stock
2024-03-20	Patel Snehal	Buy	1 500	Common Stock
2024-03-05	Patel Snehal	Buy	30 500	Common Stock
2024-03-04	Patel Snehal	Buy	4 100	Common Stock

INSIDER POWER
100.00
Last 96 transactions
Buy: 968 139 \| Sell: 271 338

Greenwich LifeSciences, 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Greenwich LifeSciences, 財務諸表

Annual	2023
収益:	$0
総利益:	$-3 612.00 (0.00 %)
EPS:	$-0.690

FY	2023
収益:	$0
総利益:	$-3 612.00 (0.00 %)
EPS:	$-0.690

FY	2022
収益:	$0
総利益:	$-3 612.00 (0.00 %)
EPS:	$-0.590

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.520

Financial Reports:

No articles found.

Greenwich LifeSciences,

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.